The FDA & CMS RAPID Program: Faster Approval Is Only Half the Story

In April 2026, the United States Food and Drug Administration (FDA) and Centers for Medicare & Medicaid Services (CMS) introduced the Regulatory Alignment for Predictable and Immediate Device (RAPID) pathway—a program designed to accelerate not just device approval, but patient access.

For medtech companies, this isn’t just another initiative. It’s a signal that the old model—approve first, figure out reimbursement later—is officially on its way out.

What Is the RAPID Program?

The RAPID pathway is a joint FDA–CMS effort to align regulatory review and Medicare coverage decisions in parallel, rather than in sequence.

Traditionally:

• FDA determines safety and effectiveness
• CMS later evaluates whether the device is “reasonable and necessary” for coverage

That gap has historically delayed patient access by months—or longer.

RAPID compresses that timeline by bringing CMS into the conversation much earlier, often during the clinical development phase.

What Makes RAPID Different?

At its core, RAPID is about early alignment and predictability.

Under the program:

• CMS engages during the IDE stage
• Sponsors receive early feedback on evidence expectations for both agencies
• CMS may issue a proposed National Coverage Determination (NCD) shortly after FDA authorization

The result: Medicare coverage decisions can follow FDA approval much faster than before.

Who Is Eligible?

RAPID is focused on:

• FDA Breakthrough Devices
• Typically Class II and Class III technologies
• Products addressing serious or life-threatening conditions

These are high-impact innovations where speed truly matters.

The Catch: Faster Doesn’t Mean Easier

If anything, RAPID raises the bar—just earlier.

• To participate, companies must:
• Design clinical studies that satisfy both FDA and CMS requirements
• Include Medicare-relevant patient populations
• Generate evidence that demonstrates not just safety and effectiveness—but clinical value in real-world use

This is where many programs will either succeed…or quietly fall apart.

Because aligning two agencies is hard. Doing it late is harder.

Why This Matters Now

RAPID fundamentally changes how companies need to think about development:

• Regulatory and reimbursement strategies can no longer operate in silos
• Clinical evidence planning must happen with dual-agency expectations in mind
• Documentation, traceability, and quality systems must support inspection-ready, submission-ready data earlier in the lifecycle

In short: you don’t get faster access without earlier discipline.

How RQMIS Helps You Win Under RAPID

This is exactly the type of environment RQMIS was built for.

The RAPID pathway rewards companies that are structured early, aligned internally, and audit-ready throughout development. That’s where we come in.

1. Integrated Regulatory & Reimbursement Strategy

We help align your FDA and CMS pathways from the start—so you’re not retrofitting evidence later.

• Breakthrough Device strategy support
• Early-stage regulatory pathway planning
• Evidence mapping to meet both FDA and CMS expectations

2. Clinical & Evidence Planning for Dual Requirements

RAPID success hinges on getting your clinical strategy right the first time.

• Protocol design incorporating Medicare populations
• Endpoint selection aligned with coverage requirements
• Gap analysis against FDA + CMS expectations

3. QMS & Design History File (DHF) Readiness

Under RAPID, documentation can’t lag behind development.

We ensure your:

• Design History File (DHF) is complete, structured, and inspection-ready
• All documentation is developed and maintained within a compliant QMS
• Traceability supports both regulatory review and reimbursement justification

Because if it’s not in the QMS, it doesn’t exist when it matters.

4. Submission & Inspection Preparedness

Speed only helps if your submission holds up under scrutiny.

• Pre-submission readiness assessments
• Technical documentation development
• FDA interaction support
• Audit and inspection preparation

5. Program Execution & Cross-Functional Alignment

RAPID requires tight coordination across teams that don’t always speak the same language.

We act as the connective tissue between:

• Regulatory
• Clinical
• Quality
• Reimbursement

So nothing falls through the cracks when timelines compress.

Final Thought

RAPID is a major step forward—but it’s not a shortcut.

It rewards companies that do the hard work earlier:

• Better planning
• Stronger documentation
• Smarter evidence strategies

The upside is real: faster access, faster adoption, and a stronger position in the market.

The risk? Moving fast without the structure to support it.

If you’re considering RAPID—or even just preparing for it—now is the time to get your foundation right.